Combined Glioblastoma Immunotherapy in Germany

A glioblastoma diagnosis is overwhelming, and the search for the right treatment can feel urgent. For patients and families looking beyond standard care, glioblastoma immunotherapy in Germany offers a targeted, innovative option worth exploring.

At GermanyHealth, we specialize in organizing personalized dendritic cell therapy in Germany. This advanced treatment is designed to train your own immune system to recognize and attack brain tumor cells. Through our partner clinics, international patients gain access to leading oncology expertise, modern facilities, and full support from the first consultation to the end of treatment.

Each therapy is built around the patient’s own immune cells and the specific profile of their tumor. The science behind it goes back to the 2011 Nobel Prize in Physiology or Medicine, awarded for discovering how dendritic cells set the immune response in motion. German centers were among the first to bring that research to the treatment of brain tumors.

In practice, this means a vaccine made from your own cells, designed to help your immune system recognize your particular tumor. Patients most often consider it when their disease hasn’t responded well to standard treatment, or when they want a targeted option to use alongside it.

What Standard Treatment Can and Cannot Do for Glioblastoma

Glioblastoma is one of the most aggressive and deadly forms of brain cancer. It grows fast and spreads into the surrounding brain tissue, which makes it extremely hard to treat. For years, the main options have been surgery, radiation, and chemotherapy.

These treatments aim to remove or shrink the tumor and slow it down, but they rarely get rid of it completely. Even with aggressive treatment, median survival is around 15 months, and the cancer often comes back.

The standard approach starts with surgery, where the goal is to remove as much of the tumor as possible without harming healthy brain tissue. Radiation follows, usually combined with the chemotherapy drug temozolomide. This combination has improved outcomes somewhat, but it often isn’t enough, because the tumor resists treatment and tends to regrow.

That’s why doctors and researchers have been pushing hard for better options, especially therapies that target the tumor at the molecular and immune level.

Surgical resection (craniotomy)

removal of as much tumor as safely possible to reduce tumor burden, relieve pressure and obtain tissue for diagnosis. Complete removal is rarely achievable due to infiltrative growth.

Radiotherapy (60 Gy in 30 fractions)

targeted radiation to the tumor region, administered over 6 weeks, typically beginning within 4 – 6 weeks of surgery.

Temozolomide (TMZ) chemotherapy

an oral alkylating agent given concurrently with radiotherapy, then as maintenance therapy for 6 cycles. Most effective in patients with MGMT-methylated tumors.

Tumor Treating Fields (TTFields / Option)

a wearable device delivering low-intensity, alternating electric fields to disrupt tumor cell division. Used alongside maintenance TMZ in eligible patients.

Re-irradiation

a second course of radiotherapy at recurrence in selected patients, delivered with a lower total dose to limit toxicity.

Bevacizumab (Avastin)

an anti-angiogenic antibody that inhibits VEGF to reduce tumor blood supply and edema. Used at recurrence; improves progression-free survival but has not clearly extended overall survival.

Palliative and supportive care

corticosteroids (dexamethasone) to reduce brain edema, anti-epileptics, rehabilitation, psychological support, and quality-of-life-focused care throughout all phases of treatment.

Clinical trials

participation in a clinical trial should always be considered, as it may provide access to novel therapies and contributes to future advances.

Why the weeks right after surgery are your most valuable window

Right after surgery, two things work in your favor: the tumor is at its smallest, and your immune system hasn’t yet been worn down by further treatment. That’s why many patients exploring glioblastoma immunotherapy in Germany consider starting oncolytic virus therapy and dendritic cell vaccination during this window. The immune system gets trained when it has the fewest cancer cells to fight, before the remaining cells have a chance to adapt and change their molecular profile.

There’s a practical side to timing, too. Standard chemoradiation usually starts within a few weeks of surgery, and it can temporarily dampen immune responses. If immunotherapy is planned around that period, instead of held back until the disease progresses, the vaccine has a much better chance of building strong, lasting immune memory.

Starting early isn’t about replacing standard care. It’s about adding to it while conditions are still on your side. The sooner the immune system learns to recognize the tumor, the better prepared it will be.

Lower tumor burden after resection means fewer cancer cells for the immune system to overcome.
The completeness of surgical removal is decided at the time of surgery — it cannot be improved later.
Chemoradiation in the weeks after surgery can temporarily suppress immune function, so timing immunotherapy for glioblastoma in Germany thoughtfully around it is reasonable.

How Your Own Immune Cells Become the Treatment

Newer treatments aim to turn the body’s own immune system against glioblastoma, and dendritic cell vaccines are one of the most promising examples. Dendritic cells (DCs) are the immune system’s messengers: they pick up fragments of the tumor, called antigens, and present them to other immune cells, helping the body recognize the cancer and attack it.

The goal is to teach the immune system to treat glioblastoma cells as a threat, something surgery, radiation, and chemotherapy can’t do on their own. In Germany, strong laboratory expertise and a legal framework that allows individual treatment attempts (individueller Heilversuch) have made this approach available to patients who choose it.

For you, the process is fully personalized. Your own tumor cells are used to create a tailored vaccine, such as IO-Vac®, which is then administered to trigger an immune response aimed specifically at their tumor.

Early studies suggest this approach may help extend survival while maintaining quality of life, since the side effects of dendritic cell vaccination are generally mild compared with conventional chemotherapy.

For many families, dendritic cell immunotherapy in Germany can be a meaningful part of a more personalized cancer care plan.

What is Dendritic Cell Vaccine for Glioblastoma?

Dendritic cells are the immune system’s most powerful antigen-presenting cells. Their job is to patrol the body, spot foreign or abnormal cells, break them down into recognizable fragments (antigens), and show those fragments to T cells, including the cytotoxic T cells that do the actual killing. This sets off a targeted immune response that can last a long time.

In people with cancer, this natural surveillance often breaks down. Tumor cells learn to suppress dendritic cells and slip past the immune system unnoticed.

A dendritic cell vaccine works around this problem. The cells are activated and primed with tumor material outside the body, in the lab, and then returned to the patient in large numbers.

Please note: this treatment is offered as an individual treatment attempt (individueller Heilversuch) under German law. It is not approved by the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA).

“The protocol in Germany is distinct from DCVax-L and other lysate-based vaccines. It is based on ICD immunogenic cell death induction via Newcastle Disease Virus prior to dendritic cell loading — a mechanistically different and more antigen-rich approach.”

Scientific Background: The Immunology and Dendritic Cell Vaccine

Clinical trials are ongoing to evaluate the safety and efficacy of immunotherapy for glioblastoma. Early results have shown promise, with some patients experiencing prolonged survival and improved quality of life. Researchers are continually refining the process to enhance the effectiveness of this therapy and reduce potential side effects.

Heat up and Destroy: Immunotherapy of “Cold” Tumors Using the Example of Glioblastoma

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

Research progress on dendritic cell vaccine in cancer immunotherapy DCs in Cancer Immunotherapy Clinical Trials: Are We Making Progress?

DCs and immunity against cancer

Antitumour dendritic cell vaccine in a priming and boosting approach

Final results of brain cancer glioblastoma clinical trial

Dendritic Cell Vaccination for Glioblastoma: Road to success or death end

Treatment of a glioblastoma patient by vaccination with autologous DCs pulsed with allogeneic major histocompatibility complex class I–matched tumor peptides

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy

Autologous tumor lysate-loaded dendritic cell therapy in glioblastoma patients: a systematic review of literature

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations

Why One Therapy Alone Is Not Enough: The Case for Combination Immunotherapy

Beyond standard treatment, several pioneering approaches are being studied and „in some centers” offered to patients, either within clinical trials or as part of integrative oncology programs. These therapies aim to harness or retrain the body’s immune system to recognize and fight GBM cells.

Why We Prime the Immune System First — Before the Vaccine

A single injection can’t build a lasting, meaningful immune response. Just as standard vaccines need booster shots, the immune system needs repeated stimulation to develop strong, long-term memory against the tumor. Here’s why the vaccine is given as a series:

The first dose is only the start. It primes “naive” T cells that haven’t met the tumor before, but the initial response is modest. Each follow-up dose multiplies these primed T cells through a process called clonal expansion, sharply increasing the number of cytotoxic T cells that can recognize and attack the tumor.
Memory takes repetition. Every vaccination strengthens immune memory. Memory T cells can circulate for months or even years and react quickly if the tumor returns, but forming them requires repeated exposure to the tumor antigens over time.
Glioblastoma fights back. The tumor’s environment actively wears down and exhausts the T cells that reach it. Repeated vaccination cycles help keep enough active T cells in play to counter this ongoing suppression.
Tumors change their disguise. Over time, tumor cells can reduce or lose some of the markers the immune system targets, a process known as antigen escape. A series of vaccinations, using broad or updated tumor antigen preparations, makes it harder for the tumor to slip away this way.
Clinical experience points the same way. In dendritic cell vaccine trials for glioblastoma, immune and clinical responses, including longer survival, were seen most consistently in patients who completed the full vaccination series.
Progress can be measured. After about three months of injections, doctors can check immune response markers to see whether the vaccine is working as intended and adjust the schedule if needed.

Why Multiple Injections Build a Stronger, Lasting Immune Response

A single injection is not sufficient to generate a durable, therapeutically meaningful immune response. The immune system requires repeated stimulation just as conventional vaccines require booster doses to build a strong, sustained anti-tumor immune memory. The following facts explain why multiple injections are necessary:

- The first injection primes naive T cells but generates only a modest primary immune response. Subsequent injections expand these primed T cell clones exponentially a process called clonal expansion dramatically increasing the number of tumor-specific CTLs.

- Each vaccination reinforces immunological memory. Memory T cells are long-lived, can circulate for months to years, and respond rapidly to tumor recurrence. This memory formation requires repeated antigen exposure over time.

- GBM’s immunosuppressive microenvironment actively depletes or exhausts tumor-infiltrating T cells. Multiple vaccination cycles help maintain an adequate pool of active effector T cells against this ongoing suppression.

- Tumor cells can down-regulate or lose individual surface antigens over time (antigen escape). Serial vaccinations loaded with diverse or updated tumor antigen preparations reduce the risk of the tumor evading the immune response through this mechanism.

- Clinical data from DC vaccine trials in GBM show that immunological and clinical responses including extended survival were observed most consistently in patients receiving the full vaccination series, not in those who received only one dose.

- Monitoring of immune response biomarkers after 3 month of injections allows clinicians to assess whether the vaccination series is generating the intended immune response and to adjust the schedule accordingly.

Think of it like a training program for your immune system.

The 5 Steps to your Vaccination

STEP 1

Leukapheresis / Blood draw

Blood is drawn and monocytes (DC precursor cells) are separated via a gentle blood-filtering procedure. This takes approximately 2- 4 hours and is done in a specialized facility. Or a simple blood draw which takes 5 min.

STEP 2

DC Maturation

In a GMP-certified laboratory, monocytes are cultured for 8 days with cytokines (IL-4, GM-CSF) to develop into immature DCs, then matured with pro-inflammatory signals.

STEP 3

ICD Immunogenic cell death

Immunogenic Cell Death (ICD) with Newcastle virus refers to a specific, immunologically active form of tumor cell death one that does not simply eliminate cells quietly, but does so in a way that raises an immune alarm.

When tumor cells die through ICD, they release or expose a series of molecular signals called Damage-Associated Molecular Patterns (DAMPs). The most important of these include calreticulin (exposed on the cell surface), HMGB1 (released into the surrounding environment), and ATP. These signals act as “danger” and “eat me” flags that recruit and activate the DCs.

STEP 4

Tumor antigen loading

Mature DCs are loaded with your-specific tumor antigens derived from the Immunogenic Cell Death (ICD) therapy with Newcastle Disease Virus (NDV) for glioblastoma.

STEP 5

Dendritic Cell Vaccine

On the 8th day you get the loaded Dendritic cells which i you glioblastoma immunotherapy in Germany which is injected typically intradermally (into your skin).

RESULT

Immunization

Injected DCs migrate to lymph nodes and present tumor antigens to naive T cells. “This activates tumor-specific cytotoxic T lymphocytes (CTLs) that travel to the tumor and attack glioblastoma cells.”

The immune response generated by glioblastoma immunotherapy in Germany is “highly specific it targets” the individual molecular fingerprint of your tumor.

However, this personalization is one of its key advantages over standard systemic therapies.

How much is the cost for Glioblastoma Immunotherapy and Dendritic Cell Vaccine Program in Germany

The honest answer is that it depends on your situation. Glioblastoma is not treated with a single fixed protocol, so the cost reflects what your individual case actually requires — the combination of therapies involved, the number of treatment cycles, the length of your stay, and the supportive care around them.

For most patients, a complete program ranges from €58K to €150K. Where your case falls within that range depends on factors such as the stage of your disease, whether you have had surgery, the treatments you have already received, and how your therapy plan is structured.

Before we can give you a meaningful figure, we need to review your medical reports.

Your imaging and treatment history tell us what is realistic and appropriate for your situation — and just as importantly, whether this therapy is a sensible option for you at all. We would rather tell you honestly that a program fits your case than quote a number that does not reflect your reality.

Once we have reviewed your reports, we prepare a personalized program evaluation. This sets out a clear treatment plan and a transparent cost estimate for your specific case, so you can make an informed decision with no surprises.

Timeline from 1st App to last App

1st Appointment / Visit

Leukapheresis / Blood draw / 1st Oncolytic Viro-therapy (5-6 days) with Newcastle virus / hyperthermia sessions (5-6 sessions) / Tecentriq injection 840 / 1680 mg and 1st Dendritic Cell Vaccination

From your first appointment until your last appointment it takes 12 days. You stay 14 nights in Germany before you fly back home.

2nd Appointment / Visit

2nd Oncolytic Viro-therapy (5-6 days) with Newcastle virus / hyperthermia sessions (5-6 sessions) and 2nd Dendritic Cell Vaccination

It also takes 12 days and you stay 14 nights in Germany before you fly back home.

3rd Appointment / Visit

Oncolytic viro-therapy (5days) with Newcastle virus plus 5 hyperthermia sessions and Immunological oncological diagnostic

You stay 7 nights this time until you are finished and ready for flying back home.

IMPORTANT!

Chemotherapy

If you are under chemotherapy it is not recommended to get dendritic cell vaccine as your immune system is weak at this time.

But, therefore we give you ICD Immunogenic cell death therapy with the Newcastle virus in order to spread your tumor antigens inside your body.

This is kind of alert for your immune system. Once you are finished with chemo we can start the program as mentioned.

Frequently asked Questions

Any query/confusion? Here’s a list of frequently-asked questions and their answers that might help.

How personalized is the therapy?

To make sure your dendritic cell vaccination hits your type of cancer, an oncolytic viro-therapy to produce tumor antigens (we call it priming) is mandatory before. After the dendritic cells are loaded with your tumor antigens.

Are there side effects, and how severe are they?

“Yes, like all medical treatments, dendritic cell therapy and other immunotherapies can have side effects—but they are generally much milder compared to chemotherapy or radiation. Most patients experience only mild flu-like symptoms such as fatigue, fever, or soreness at the injection site.

However, these effects usually go away within a day or two. Serious side effects are rare, especially with dendritic cell therapy, because it works with your body’s natural immune system.

However, we closely monitor every patient and personalize the treatment to minimize risks as much as possible.”

Side effects exist but are typically mild.
Dendritic cell vaccine is known for being well-tolerated.
Monitoring and personalization reduce risks.
Compared to chemo or radiation, the body handles it much better.

What is the success rate of dendritic cell therapy?

“The success rate of DCT depends strongly on the type and stage of your cancer, as well as your overall health and how your immune system responds.

However, in some cancers like melanoma, non-small cell lung cancer, glioblastoma, pancreatic cancer, prostate cancer or certain lymphomas, immunotherapy has shown significant success—even complete remission in some cases.

For other cancers, it may be used to slow progression, improve quality of life, or support other treatments.

That’s why we offer personalized evaluations to determine if this therapy is likely to be effective in your specific case. Hence the goal of GermanyHealth is always to find the best approach for your unique condition.”

How many dendritic cell therapy cycles are required?

The number of dendritic cell (DC) therapy cycles required can vary depending on the type of cancer, stage, patient’s immune response, and the specific protocol used by the treatment center.

However, you need an oncolytic viro-therapy to expose the tumor antigens:

Most clinical protocols recommend:

2 to 6 cycles of dendritic cell vaccination often one cycle every 2–4 weeks.

Why Multiple Cycles Are Needed?

Immune Activation Takes Time.

Hence, this process strengthens gradually with repeated exposure to the tumor antigens.

Dendritic cells need to “educate” the immune system specifically T cells to recognize and attack cancer cells.

Memory T Cell Development

Repeated dosing helps create long-lasting immune memory, which is crucial for preventing recurrence.

Tumor Burden and Immune Suppression

Cancer can suppress immune function. Multiple cycles help overcome tumor-induced immune tolerance and sustain immune activation.

Monitoring and Adaptation

After each cycle, doctors evaluate immune markers (like cytotoxic T cell activity, cytokine levels) and tumor response (imaging or tumor markers).
Depending on progress, further cycles may be added or adjusted.

How soon can I start, and how long does it take?

Normally within 10-14 days.

Our Experts of Glioblastoma Immunotherapy in Germany

Prof. Dr. med. van Gool

Van Gool, MD, PhD, is a specialist in pediatric and adult hematology-oncology with a focus on brain tumors but also center in general.

“Since every tumor is different, the best results are achieved by using the patient’s own dendritic cells to attack the unique set of tumor cells.”

Dr. rer. nat. Nesselhut

Dr. Nesselhut is specialist in Immunotherapies and board certified physician in immunotherapy. His focus is at oncologically immunotherapy and DCV.

“We are focused on the human being in its entirety.”

Dr. med. Stücker

Dr. Stücker counts among the renowned scientists and physicians in the fields of immuno-oncology and translational oncology.

“We use our expertise to extend the lives of cancer patients and offer them gentle treatment.”

Testimonials

Mr. Martin became my friend and I'm glad I met a company like GermanyHealth.

Ulf, Norway

Prostate cancer

All went perfect. Thank you to the team of GermanyHealth.

Monika, Hungary

Adenocarcinoma (Skin)

"I want to say thank you to GermanyHealth.These guys organized according to my expectations!

Stefani, USA

Ovarian cancer

Perfect organization. Me and my wife didn't miss anything. Thanks a lot

Reggi, USA

Pancreatic cancer

Find a clinic for Dendritic Cell Vaccine in Germany

Germany is renowned for its advanced medical treatments and state-of-the-art facilities, making it a top destination for patients seeking cutting-edge therapies like comprehensive immunotherapy. One of the leading organizations in this field is GermanyHealth.

Our offer includes all from A to Z including transportation if you need it. Hence, for a remote second opinion, book here. However, if you have high demand, we recommend booking our VIP Service Germany.

Also our patient service provides comprehensive support for international patients seeking treatment with dendritic cell vaccine for glioblastoma in Germany.

Expert Consultation and Treatment Planning: We provide expert medical consultation to determine the most appropriate treatment plan for each patient with glioblastoma to get the appropriate dendritic cell therapy.

Hospital and Clinic Coordination: We arrange treatment at some of Germany’s best hospitals and clinics specializing in the treatment of glioblastoma with modern Immunotherapies. Of course, you receive our onside service as well.

Travel and Accommodation Assistance: We assist with travel arrangements, visa applications, transportation in Germany, and accommodation, ensuring a smooth and stress-free experience.

Ongoing Patient Support: We offer continuous support throughout the treatment process, including follow-up care and communication with the clinic. Hence, we provide follow up service after you have left back home.

Glioblastoma Immunotherapy in Germany